

## Curriculum Vitae

### Dr. Duncan McHale

#### Personal data

Year of birth: 1966

Nationality: British

Independence: +

#### Member of the Supervisory Board of Evotec

First appointment: 2024

Current term of office: General Annual Meeting 2024 – 2026

Committees: ESG Committee

#### Competences and experiences

Extensive experience in the Discovery and worldwide Development of medicines with a particular focus on translational medicine, early drug development and Personalized Medicine. Experience at large and medium pharmaceutical companies as well as multiple biotechnology companies. Worked across many therapeutic modalities including small molecule, large molecule, siRNA, cell therapies and oncolytic viruses. Worked across many different disease areas, including immunology, oncology, dermatology, gastroenterology, cardiology, neurology and bone diseases. Experience across multiple biomarker platforms including genetics, transcriptomics, proteomics, metabolomics and imaging. Executive leadership positions in the biopharmaceutical industry for more than 20 years, resulting in progressing over 25 programs into first-in-human studies. Using a strong scientific background combined with broad clinical research expertise has driven significant changes in early drug development across multiple companies including use of biomarkers, adaptive trial designs, Bayesian statistics and PK PD modelling to inform dose predictions. A long-standing career as an early drug developer and Chief Medical Officer with deep experience in translational medicine and personalized healthcare. Experience of multiple partnership programs with Pharma partners including membership of multiple steering committees on specific drug programs and broader multi-company partnerships on technology development. Founded a drug development consultancy organization which has grown to over 40 FTEs in 7 years and as a consultant to multiple biotech companies from 2017 to 2024, have experience of raising capital, buy and sell due diligence, development of corporate strategy, business development strategy and possesses in-depth knowledge and experience in general management, data-enabled innovation and risk management.

Experience as a member of multiple public committees including government advisory committees on human genetics and emerging science and biotechnology as well as Medical Research Committees on stratified Medicine and Clinical Pharmacology. Experience drafting joint industry and regulatory drug development guidelines as a member of the ICH E15 and E16 committees. Has been a member of multiple joint steering committees managing partnerships.

**Current occupation:**

Co-Founder and Senior Development Clinician at Weatherden Limited, London, UK

Chair of SynaptraBIO Ltd, Sydney, AUS

**Career highlights:**

2017 – current	Weatherden Limited; Founder and director
2018 – 2023	Evelo Biosciences; Chief Medical Officer
2011 – 2017	UCB Pharma; Global Head of Exploratory Development
2008 – 2011	AstraZeneca; Vice President of Translational Sciences

**Qualifications:**

2010-2015	Professor of Clinical Pharmacology (visiting), University of Liverpool
2000	PhD, University of Leeds
1991	Bachelor of Medicine and Bachelor of Surgery (medical degree), University of Newcastle
1990	B.Med.Sci. (first class), University of Newcastle

**Current mandates in listed companies:**

Evotec SE, Hamburg/Germany                      Member of the Supervisory Board  
(listed on the Frankfurt Stock Exchange  
and NASDAQ, New York)

**Previous mandates in non-commercial public organizations:**

UK Government	Member of the Emerging Science and Bioethics Advisory Committee
UK Human Genetics Commission	Member
Medical Research Council	Chair of the Stratified Medicine Governance Committee; Member of the Discovery Awards program Committee; Clinical Training Fellowship (panel); Clinical Training Fellowship in Pharmacology (Steering Committee and panel)

**Previous Leadership Roles on Industry Committees:**

Association of the British Pharmaceutical Industry (ABPI)	Chair of the UK Stratified Medicine Initiative
Innovative Medicine Initiative (IMI)	Lead on call for Molecular Taxonomy of Human Disease
European Federation of Pharmaceutical Industries and Associations (EFPIA)	Chair of the Pharmacogenetics and Pharmacogenomics ad hoc working group
International Conference on Harmonization (ICH)	European Industry Representative to the Genomic biomarker ICH working party and co Rapporteur for ICH Expert Topic E15 and E16 (Genomic Biomarker Qualification Working group)

*Latest update: February 2026*